InsideArbitrage Event Driven Monitor – August 28, 2023

Subscribe to receive our Event Driven Monitor by email every morning before the market opens.

Merger Arbitrage

1. HZNP: The FTC withdrew an in-house trial over its opposition to Amgen’s (AMGN) acquisition of Horizon Therapeutics (HZNP).
2. BKI: Intercontinental Exchange (ICE) and Black Knight (BKI) entered into a consent agreement with the FTC over ICE’s planned acquisition of Black Knight.
3. DBTX: Decibel Therapeutics announced that the U.S. Food and Drug Administration had granted fast track designation for DB-OTO, the company’s lead gene therapy product candidate for congenital hearing loss caused by mutations of the otoferlin gene.

Only plus or premium subscribers can access this post. Subscribe today.